| Name | Title | Contact Details |
|---|
The Word & Brown Companies, headquartered in Orange, Calif., provides services through more than 50,000 brokers to nearly 60,000 employers with more than 6 million eligible employees. During its more than 20-year-span, The Word & Brown Companies has become the nation’s recognized leader in developing and offering innovative technology, health benefit plan models, and sophisticated employee benefits services to companies of all sizes. The Word & Brown Companies includes: Word & Brown General Agency, the leader in developing and distributing health benefit plan models and solutions to licensed brokers in California and Nevada; CHOICE Administrators, the nation’s leader in developing and administrating employee-choice health benefit programs; CONEXIS, providing benefits solutions to clients nationwide, with expertise in COBRA and HIPAA administrative services, Direct Bill Services, and Flexible Benefits Administration, including Flexible Spending Accounts (FSA) and Section 132 Commuter Benefits; Quotit Corporation the leading Internet application service provider for the health insurance/employee benefits industry; and HealthCompare, which works with brokers and carriers to help individuals and families easily research, compare, buy, and enroll in the right health insurance plan at the right price.
Grey Stragetic Market Conditioning is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CollaborateMD was founded in 1999 to help medical practices and medical billing services thrive in the jungle of ever changing government and insurance payer regulations without having to spend a fortune on software, support, and hardware.
Saint Lukes Health System is a non-profit hospital network in the bi-state Kansas City metro area, located in northeast Kansas and northwest Missouri.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.